Pharmaceutical manufacturer Neimeth International Pharmaceuticals Plc reported an operating profit of ₦5.01 billion in its 2025 full-year results, a marked improvement over previous years. The company highlighted that operating profit grows to N5.01bn in 2025 results, underscoring a turnaround in its core operations.
Revenue growth has been robust: the company’s turnover climbed sharply in recent quarters, with one report showing an 86 % rise in Q1 2025 compared with Q1 2024. Gross profit also expanded significantly, signalling that the business is improving not just in scale but in margin. The result reflects gains from its pharmaceutical manufacturing and animal-health divisions, where increased product uptake and improved route-to-market strategies featured strongly.
However, the company still faces headwinds. Finance costs and foreign-exchange losses have weighed on its bottom line in earlier periods. Management has responded by restructuring foreign-denominated loans and prioritising naira-based sourcing to reduce currency exposure.
Going forward, Neimeth is focused on executing its 2025-2029 strategic growth plan, which includes further investment in manufacturing capacity, research and development, and African market expansion. One notable effort is the upgrade of its Lagos facility to align with global manufacturing standards and the development of a new plant in Anambra State to serve the broader African market.
With the operating profit milestone now behind it, Neimeth appears to be entering a phase of sustainable growth, though continued discipline over costs, financing and currency risk will be essential if it is to translate this operating success into consistent net-profit growth and dividends.
The surge in Neimeth’s profitability comes at a time when Nigeria’s economy is grappling with currency volatility, high borrowing costs and weakened consumer purchasing power. A stronger local pharmaceutical sector not only boosts domestic manufacturing and reduces import exposure, but also contributes to job creation, investment inflows and improved supply chain resilience in the health-care industry.
